REMEVi — NAD+ route, dose and price
REMEVi is not a partner — this company pays us nothing, and it is listed anyway.
REMEVi publishes a floor only for NAD+, across 1 distinct figure read from its own page.
1 figure, by route
| Route | Dose | Price |
|---|---|---|
| SubQ | dose not stated | $145NAD+ · 4-WEEK SUBSCRIPTION |
advertised floor for a vial and syringes ONE PRICE, THREE ROUTES. Recorded once under subcutaneous because that is the page's headline product ('NAD+ injections, prescribed online.'), but the same $145 buys the nasal spray or the oral dropper — do not create separate per-route prices for this seller and do not treat nasal/oral as unpriced. The page describes the same figure two ways: 'FROM $145 / 4 weeks · all-inclusive' (hero and sticky footer) and '$145 flat 4-week subscription · all-inclusive' (stats row); both quoted, neither classified. The cycle is 4 weeks, and the pricing card labels it 'FOUNDER'S PRICING' — recorded as the seller's word, not interpreted.
| ||
We are paid nothing if you sign up here.
What else the page states
- Routes this seller names
- SubQ
- Where the link goes
- Straight to this company's own NAD+ page.
Where REMEVi sits
On the full roster it is row 71 of 106. That roster is ordered by what each seller states about its own figures and by nothing else — payment changes neither a price recorded here nor where a row sits.
We are paid nothing if you sign up here.
Prices move. Everything above was read on September 2026 and is republished with that date attached; check REMEVi’s own page before you buy.